Callan Capital, LLC Cardiff Oncology, Inc. Transaction History
Callan Capital, LLC
- $1.42 Billion
- Q3 2024
A detailed history of Callan Capital, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 91,467 shares of CRDF stock, worth $232,326. This represents 0.02% of its overall portfolio holdings.
Number of Shares
91,467
Previous 65,047
40.62%
Holding current value
$232,326
Previous $144,000
69.44%
% of portfolio
0.02%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$6.68 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.52 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$2.36 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$2.11 Million0.0% of portfolio
-
Mai Capital Management663KShares$1.68 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $110M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...